Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Diabetes medication management Clear all
Suspended Not applicable Interventional

A Study to Improve Diabetes Management Among Adults Experiencing Severe Hypoglycemia

NCT04874532
View directory record Official record
Conditions
Diabetes, Hypoglycemia, Diabetes Type 1, Diabetes Type 2
Interventions
Community Paramedic Program, Education Material
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Not applicable Interventional

A Comprehensive Community Approach for Diabetes Prevention and Care for a Vulnerable Population in Galveston

NCT05097534
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
iDSMES, Standard of Care
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
13 Years to 84 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 28, 2026, 6:10 PM EDT
Active, not recruiting Not applicable Interventional

Resilience-Based Diabetes Self-Management Education (RB-DSME) for African Americans

NCT04282395
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Resilience-Based Diabetes Self-Management Education, Standard Diabetes Self-Management Education
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 4 Interventional Results available

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

NCT05035082
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
semaglutide, oral glucose-lowering medications (commercially available)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Alhambra, California • Costa Mesa, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Not applicable Interventional Results available

Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients

NCT03039569
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Text messaging
Behavioral
Lead sponsor
University of Nebraska Lincoln
Other
Eligibility
30 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Diabetes Self-Management Models to Reduce Health Disparities

NCT01221090
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
PDA, CDSMP, PDA/CDSMP
Behavioral
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2013 · Synced Sep 28, 2026, 6:10 PM EDT
Withdrawn Phase 3 Interventional

Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes

NCT00754689
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rimonabant, Metformin, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Not applicable Interventional Results available

Impact of Pharmacy Clinic on Diabetes Management

NCT03377127
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pharmacy Managed Diabetes Clinic (PMDC), Standard of Care (SOC)
Behavioral · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Berkley, Michigan • Royal Oak, Michigan • Southfield, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 28, 2026, 6:10 PM EDT
Active, not recruiting Phase 2 Interventional

An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer

NCT04742751
View directory record Official record
Conditions
PreDiabetes, Adult Children
Interventions
Metformin, Digital Intervention
Drug · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 44 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 3 Interventional

A Pragmatic Approach to Lower Diabetes Risk After Gestational Diabetes

NCT05280496
View directory record Official record
Conditions
Diabetes, Gestational, PreDiabetes, Diabetes Mellitus, Type 2
Interventions
Metformin
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

NCT04075513
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 28, 2026, 6:10 PM EDT
Withdrawn Phase 3 Interventional

Empaglifozin in Early Diabetic Kidney Disease

NCT03173963
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetes Mellitus Type 2
Interventions
Empagliflozin, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Not applicable Interventional

Healthy Mediation Adherence To Transform and Effectively Relieve Symptoms

NCT04656093
View directory record Official record
Conditions
COPD, Diabetes, Hypertension
Interventions
Supportive counseling, Education on SMB, Psychoeducation on ATs for maladaptive beliefs (if applicable), Psychoeducation on emotional response (if applicable)
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Not applicable Interventional Results available

Technology-assisted Case Management in Adults With Type 2 Diabetes

NCT01373489
View directory record Official record
Conditions
Diabetes
Interventions
Technology-Assisted Case Management
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 120 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 28, 2026, 6:10 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

NCT03713684
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Efpeglenatide SAR439977, Placebo, Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Not applicable Interventional Results available

Use of the Guardian™ Connect System With Smart Connected Devices

NCT04809285
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
14
States / cities
Little Rock, Arkansas • Loma Linda, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Not applicable Interventional Results available

Community Servings: Food as Medicine for Diabetes

NCT02426138
View directory record Official record
Conditions
Diabetes
Interventions
Medically Tailored Meal Delivery (MTM), Usual Care + Choose MyPlate
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

NCT02058147
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
118
States / cities
Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 28, 2026, 6:10 PM EDT
Not listed Not applicable Interventional

Lifestyle Intervention to Reduce Body Weight and Systemic Inflammation Among World Trade Center Responders

NCT05138198
View directory record Official record
Conditions
Post-Traumatic Stress Disorder, Overweight and Obesity, Metabolic Syndrome, Inflammation
Interventions
Mediterranean Diet & Physical Activity, Usual Care
Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
40 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Commack, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Not applicable Interventional

Phipps Conservatory's 5210 Let's Move Pittsburgh and Impact on Youth With T1D

NCT07780487
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Virtual cooking classes, Routine Diabetes Care
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Not applicable Interventional

Evaluating the Cost Effectiveness of STEADI

NCT05390736
View directory record Official record
Conditions
Accidental Fall
Interventions
Gait and balance assessment, Medication review, Comorbidity review, Fall history, Assessment of feet/footwear, Assessment of visual acuity, Home safety risk assessment, Vitamin D Deficiency
Behavioral
Lead sponsor
National Opinion Research Center
Other
Eligibility
65 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 28, 2026, 6:10 PM EDT